224 related articles for article (PubMed ID: 36922932)
21. Durable Molecular Remissions in Chronic Lymphocytic Leukemia Treated With CD19-Specific Chimeric Antigen Receptor-Modified T Cells After Failure of Ibrutinib.
Turtle CJ; Hay KA; Hanafi LA; Li D; Cherian S; Chen X; Wood B; Lozanski A; Byrd JC; Heimfeld S; Riddell SR; Maloney DG
J Clin Oncol; 2017 Sep; 35(26):3010-3020. PubMed ID: 28715249
[TBL] [Abstract][Full Text] [Related]
22. Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia.
Porter DL; Hwang WT; Frey NV; Lacey SF; Shaw PA; Loren AW; Bagg A; Marcucci KT; Shen A; Gonzalez V; Ambrose D; Grupp SA; Chew A; Zheng Z; Milone MC; Levine BL; Melenhorst JJ; June CH
Sci Transl Med; 2015 Sep; 7(303):303ra139. PubMed ID: 26333935
[TBL] [Abstract][Full Text] [Related]
23. Immunostimulatory CpG-oligonucleotides cause proliferation, cytokine production, and an immunogenic phenotype in chronic lymphocytic leukemia B cells.
Decker T; Schneller F; Sparwasser T; Tretter T; Lipford GB; Wagner H; Peschel C
Blood; 2000 Feb; 95(3):999-1006. PubMed ID: 10648415
[TBL] [Abstract][Full Text] [Related]
24. Chronic lymphocytic leukemia B cells can express CD40 ligand and demonstrate T-cell type costimulatory capacity.
Schattner EJ; Mascarenhas J; Reyfman I; Koshy M; Woo C; Friedman SM; Crow MK
Blood; 1998 Apr; 91(8):2689-97. PubMed ID: 9531577
[TBL] [Abstract][Full Text] [Related]
25. HSV amplicon-mediated delivery of LIGHT enhances the antigen-presenting capacity of chronic lymphocytic leukemia.
Tolba KA; Bowers WJ; Eling DJ; Casey AE; Kipps TJ; Federoff HJ; Rosenblatt JD
Mol Ther; 2002 Oct; 6(4):455-63. PubMed ID: 12377186
[TBL] [Abstract][Full Text] [Related]
26. Optimization of anti-CD19 CAR T cell production for treatment of patients with chronic lymphocytic leukemia.
Amatya C; Weissler KA; Fellowes V; Lam N; Cutmore LC; Natrakul DA; Highfill SL; Kochenderfer JN
Mol Ther Methods Clin Dev; 2024 Mar; 32(1):101212. PubMed ID: 38455264
[TBL] [Abstract][Full Text] [Related]
27. Autologous CD19-Targeted CAR T Cells in Patients with Residual CLL following Initial Purine Analog-Based Therapy.
Geyer MB; Rivière I; Sénéchal B; Wang X; Wang Y; Purdon TJ; Hsu M; Devlin SM; Halton E; Lamanna N; Rademaker J; Sadelain M; Brentjens RJ; Park JH
Mol Ther; 2018 Aug; 26(8):1896-1905. PubMed ID: 29910179
[TBL] [Abstract][Full Text] [Related]
28. Chronic lymphocytic leukemia cells impair mitochondrial fitness in CD8
van Bruggen JAC; Martens AWJ; Fraietta JA; Hofland T; Tonino SH; Eldering E; Levin MD; Siska PJ; Endstra S; Rathmell JC; June CH; Porter DL; Melenhorst JJ; Kater AP; van der Windt GJW
Blood; 2019 Jul; 134(1):44-58. PubMed ID: 31076448
[TBL] [Abstract][Full Text] [Related]
29. Costimulatory domains direct distinct fates of CAR-driven T-cell dysfunction.
Selli ME; Landmann JH; Terekhova M; Lattin J; Heard A; Hsu YS; Chang TC; Chang J; Warrington J; Ha H; Kingston N; Hogg G; Slade M; Berrien-Elliott MM; Foster M; Kersting-Schadek S; Gruszczynska A; DeNardo D; Fehniger TA; Artyomov M; Singh N
Blood; 2023 Jun; 141(26):3153-3165. PubMed ID: 37130030
[TBL] [Abstract][Full Text] [Related]
30. Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia.
Fraietta JA; Lacey SF; Orlando EJ; Pruteanu-Malinici I; Gohil M; Lundh S; Boesteanu AC; Wang Y; O'Connor RS; Hwang WT; Pequignot E; Ambrose DE; Zhang C; Wilcox N; Bedoya F; Dorfmeier C; Chen F; Tian L; Parakandi H; Gupta M; Young RM; Johnson FB; Kulikovskaya I; Liu L; Xu J; Kassim SH; Davis MM; Levine BL; Frey NV; Siegel DL; Huang AC; Wherry EJ; Bitter H; Brogdon JL; Porter DL; June CH; Melenhorst JJ
Nat Med; 2018 May; 24(5):563-571. PubMed ID: 29713085
[TBL] [Abstract][Full Text] [Related]
31. Effects of preactivated autologous T lymphocytes on CD80, CD86 and CD95 expression by chronic lymphocytic leukemia B cells.
Romano C; De Fanis U; Sellitto A; Dalla Mora L; Chiurazzi F; Giunta R; Rotoli B; Lucivero G
Leuk Lymphoma; 2003 Nov; 44(11):1963-71. PubMed ID: 14738151
[TBL] [Abstract][Full Text] [Related]
32. IFN-alpha stimulates proliferation and cytokine secretion of CD40-stimulated B cell chronic lymphocytic leukemia cells in vitro.
Brass U; Tretter T; Schneller F; Schuler M; Huber C; Peschel C
J Interferon Cytokine Res; 1999 Apr; 19(4):335-43. PubMed ID: 10334384
[TBL] [Abstract][Full Text] [Related]
33. Treatment of chronic lymphocytic leukemia requires targeting of the protective lymph node environment with novel therapeutic approaches.
Hayden RE; Pratt G; Roberts C; Drayson MT; Bunce CM
Leuk Lymphoma; 2012 Apr; 53(4):537-49. PubMed ID: 21812539
[TBL] [Abstract][Full Text] [Related]
34. CD3xCD19 DART molecule treatment induces non-apoptotic killing and is efficient against high-risk chemotherapy and venetoclax-resistant chronic lymphocytic leukemia cells.
Martens AWJ; Janssen SR; Derks IAM; Adams Iii HC; Izhak L; van Kampen R; Tonino SH; Eldering E; van der Windt GJW; Kater AP
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32581054
[TBL] [Abstract][Full Text] [Related]
35. Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia.
Fraietta JA; Beckwith KA; Patel PR; Ruella M; Zheng Z; Barrett DM; Lacey SF; Melenhorst JJ; McGettigan SE; Cook DR; Zhang C; Xu J; Do P; Hulitt J; Kudchodkar SB; Cogdill AP; Gill S; Porter DL; Woyach JA; Long M; Johnson AJ; Maddocks K; Muthusamy N; Levine BL; June CH; Byrd JC; Maus MV
Blood; 2016 Mar; 127(9):1117-27. PubMed ID: 26813675
[TBL] [Abstract][Full Text] [Related]
36. Expanded antigen-experienced CD160
Bozorgmehr N; Okoye I; Oyegbami O; Xu L; Fontaine A; Cox-Kennett N; Larratt LM; Hnatiuk M; Fagarasanu A; Brandwein J; Peters AC; Elahi S
J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33931471
[TBL] [Abstract][Full Text] [Related]
37. CAR T Cell Therapy in Acute Lymphoblastic Leukemia and Potential for Chronic Lymphocytic Leukemia.
Singh N; Frey NV; Grupp SA; Maude SL
Curr Treat Options Oncol; 2016 Jun; 17(6):28. PubMed ID: 27098534
[TBL] [Abstract][Full Text] [Related]
38. Tumor-intrinsic CD21 expression impacts the response of B-cell malignancy cells to CD19-CAR-T cells.
Li D; Xu Q; Hu Y; Wang W; Xie S; Zhao C; Liu H
J Leukoc Biol; 2022 Oct; 112(4):913-918. PubMed ID: 35338522
[TBL] [Abstract][Full Text] [Related]
39. Lenalidomide treatment promotes CD154 expression on CLL cells and enhances production of antibodies by normal B cells through a PI3-kinase-dependent pathway.
Lapalombella R; Andritsos L; Liu Q; May SE; Browning R; Pham LV; Blum KA; Blum W; Ramanunni A; Raymond CA; Smith LL; Lehman A; Mo X; Jarjoura D; Chen CS; Ford R; Rader C; Muthusamy N; Johnson AJ; Byrd JC
Blood; 2010 Apr; 115(13):2619-29. PubMed ID: 19965642
[TBL] [Abstract][Full Text] [Related]
40. Valproic acid increases CAR T cell cytotoxicity against acute myeloid leukemia.
Wen J; Chen Y; Yang J; Dai C; Yu S; Zhong W; Liu L; He C; Zhang W; Yang T; Liu L; Hu J
J Immunother Cancer; 2023 Jul; 11(7):. PubMed ID: 37524506
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]